CONTAIN CONCERNING LEVELS OF LEAD. WHETHER YOU’RE REACHING FOR CRUNCHY SNACKS OR GLUTEN FREE COMFORT FOODS, CASSAVA IS SHOWING UP IN MORE PRODUCTS THAN EVER. BUT BEHIND THE HEALTH HALO LIES A ...

Cassava Technologies has announced yet another partnership in its goal of driving Africa’s artificial intelligence (AI) future. This time, they signed a Memorandum of Understanding (MoU) with ...

Cassava Technologies — the parent company of Liquid and Africa Data Centres — has signed a deal with Zindi, an African platform that runs data science competitions. The two plan to collaborate ...

Objective: To establish the current body of evidence regarding the safety of cassava and cassava-based products for human consumption and to identify the most effective preparation methods to reduce ...

Cassava Technologies may invest as much as US$720-million (R14-billion) in Africa’s first artificial intelligence factory that will be built by Nvidia. The pan-African technology firm founded by ...

Throughout the world, an estimated 800 million people consider cassava root a staple part of their diet. This starchy tuber—also known as yuca, Brazilian arrowroot, and manioc—first originated in ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental ...

NEW YORK, March 26 (Reuters) - The biotechnology company Cassava Sciences (SAVA.O), opens new tab failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. Months after seeing one phase 3 trial fail, the biotech is planning to stop development altogether after chalking up another ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.” After ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...